Cardio-Oncology Fellowship Training and Education

被引：2
作者：
Fradley M.G. [1 ]
机构：
[1] Cardio-Oncology Program, Division of Cardiovascular Medicine, Morsani College of Medicine and H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 USF Magnolia Dr., MCB-CPT, Tampa, 33612-9416, FL
来源：
Current Treatment Options in Cardiovascular Medicine | 2019年 / 21卷 / 6期
关键词：
Cardio-oncology; Cardiotoxicity; Education; Fellowship;
D O I：
10.1007/s11936-019-0733-4
中图分类号：
学科分类号：
摘要：
Purpose of review: With the rapid development of novel cancer therapeutics and the growing number of cancer survivors, there is significant demand for cardio-oncology experts to care for these patients. As such, it has become increasingly necessary to develop formalized training in the field of cardio-oncology. This review will focus on the current state of cardio-oncology education, with recommendations for the development of dedicated cardio-oncology fellowships. Recent findings: Cardio-oncology fellowships should be affiliated with high-volume centers that have established cardio-oncology clinical and research programs with dedicated cardio-oncology faculty. Several recent publications have proposed recommendations to develop uniform cardio-oncology training standards, core curricula, and evaluation metrics. Summary: With the rapid evolution of the field and the support of various profession organizations, the number and quality of dedicated cardio-oncology fellowship programs is expected to increase significantly. The adoption of defined training requirements and evaluation standards to measure competency will be essential to ensure the legitimacy and success of the field. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
相关论文
共 57 条
[41]  
Brown J.R., Moslehi J., O'Brien S., Ghia P., Hillmen P., Cymbalista F., Et al., Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials, Haematologica, 102, 10, pp. 1796-1805, (2017)
[42]  
Feliz V., Saiyad S., Ramarao S.M., Khan H., Leonelli F., Guglin M., Melphalan-induced supraventricular tachycardia: incidence and risk factors, Clin Cardiol, 34, 6, pp. 356-359, (2011)
[43]  
Outomuro D., Grana D.R., Azzato F., Milei J., Adriamycin-induced myocardial toxicity: new solutions for an old problem?, Int J Cardiol, 117, 1, pp. 6-15, (2007)
[44]  
Ganatra S., Sharma A., Shah S., Chaudhry G.M., Martin D.T., Neilan T.G., Mahmood S.S., Barac A., Groarke J.D., Hayek S.S., Dani S., Venesy D., Patten R., Nohria A., Ibrutinib-associated atrial fibrillation, JACC Clin Electrophysiol, 4, 12, pp. 1491-1500, (2018)
[45]  
Guha A., Derbala M.H., Zhao Q., Wiczer T.E., Woyach J.A., Byrd J.C., Awan F.T., Addison D., Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies, J Am Coll Cardiol, 72, 6, pp. 697-698, (2018)
[46]  
Fradley M.G., Moslehi J., QT prolongation and oncology drug development, Card Electrophysiol Clin, 7, 2, pp. 341-355, (2015)
[47]  
Naing A., Veasey-Rodrigues H., Hong D.S., Fu S., Falchook G.S., Wheler J.J., Tsimberidou A.M., Wen S., Fessahaye S.N., Golden E.C., Aaron J., Ewer M.S., Kurzrock R., Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs, Ann Oncol, 23, 11, pp. 2960-2963, (2012)
[48]  
Armanious M.A., Mishra S., Fradley M.G., Electrophysiologic toxicity of chemoradiation, Curr Oncol Rep, 20, 6, (2018)
[49]  
Tartarone A., Gallucci G., Lazzari C., Lerose R., Lombardi L., Aieta M., Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management, Future Oncol, 11, 14, pp. 2043-2048, (2015)
[50]  
Johnson D.B., Balko J.M., Compton M.L., Chalkias S., Gorham J., Xu Y., Hicks M., Puzanov I., Alexander M.R., Bloomer T.L., Becker J.R., Slosky D.A., Phillips E.J., Pilkinton M.A., Craig-Owens L., Kola N., Plautz G., Reshef D.S., Deutsch J.S., Deering R.P., Olenchock B.A., Lichtman A.H., Roden D.M., Seidman C.E., Koralnik I.J., Seidman J.G., Hoffman R.D., Taube J.M., Diaz L.A., Anders R.A., Sosman J.A., Moslehi J.J., Fulminant myocarditis with combination immune checkpoint blockade, N Engl J Med
123456